A Novel Hybrid Nanosystem Integrating Cytotoxic and Magnetic Properties as a Tool to Potentiate Melanoma Therapy.

Cuphen iron oxide nanoparticles magnetic targeting melanoma therapy nanoparticles safety pH-sensitive liposomes

Journal

Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216

Informations de publication

Date de publication:
06 Apr 2020
Historique:
received: 29 02 2020
revised: 27 03 2020
accepted: 31 03 2020
entrez: 10 4 2020
pubmed: 10 4 2020
medline: 10 4 2020
Statut: epublish

Résumé

Cancer is a major health concern and the prognosis is often poor. Significant advances in nanotechnology are now driving a revolution in cancer detection and treatment. The goal of this study was to develop a novel hybrid nanosystem for melanoma treatment, integrating therapeutic and magnetic targeting modalities. Hence, we designed long circulating and pH-sensitive liposomes loading both dichloro(1,10-phenanthroline) copper (II) (Cuphen), a cytotoxic metallodrug, and iron oxide nanoparticles (IONPs). The synthetized IONPs were characterized by transmission electron microscopy and dynamic light scattering. Lipid-based nanoformulations were prepared by the dehydration rehydration method, followed by an extrusion step for reducing and homogenizing the mean size. Liposomes were characterized in terms of incorporation parameters and mean size. High Cuphen loadings were obtained and the presence of IONPs slightly reduced Cuphen incorporation parameters. Cuphen antiproliferative properties were preserved after association to liposomes and IONPs (at 2 mg/mL) did not interfere on cellular proliferation of murine and human melanoma cell lines. Moreover, the developed nanoformulations displayed magnetic properties. The absence of hemolytic activity for formulations under study demonstrated their safety for parenteral administration. In conclusion, a lipid-based nanosystem loading the cytotoxic metallodrug, Cuphen, and displaying magnetic properties was successfully designed.

Identifiants

pubmed: 32268611
pii: nano10040693
doi: 10.3390/nano10040693
pmc: PMC7221742
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fundação para a Ciência e Tecnologia (FCT) Portugal
ID : UID/DTP/04138/2019
Organisme : Fundação para a Ciência e Tecnologia (FCT), Portugal
ID : PTDC/BTM-SAL/28977/2017
Organisme : Fundação para a Ciência e Tecnologia (FCT) Portugal
ID : PTDC/MED-QUI/31721/2017
Organisme : Fundação para a Ciência e Tecnologia (FCT), Portugal
ID : UIDB/00645/2020
Organisme : Fundação para a Ciência e Tecnologia (FCT), Portugal
ID : UID/AMB/50017/2019
Organisme : Fundação para a Ciência e Tecnologia (FCT), Portugal
ID : SFRH/BD/117586/2016

Références

Oncologist. 2011;16(1):5-24
pubmed: 21212434
Expert Opin Ther Pat. 2017 Jan;27(1):49-62
pubmed: 27622909
Nano Lett. 2016 Sep 14;16(9):5652-60
pubmed: 27541372
J Clin Oncol. 2008 Feb 1;26(4):527-34
pubmed: 18235113
Nanotechnology. 2012 Jun 1;23(21):215602
pubmed: 22551699
Cochrane Database Syst Rev. 2018 Feb 06;2:CD011123
pubmed: 29405038
ACS Appl Mater Interfaces. 2020 Jan 29;12(4):4295-4307
pubmed: 31904927
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
PLoS One. 2012;7(5):e37435
pubmed: 22624030
J Trace Elem Med Biol. 2016 Dec;38:53-63
pubmed: 27056797
Chem Soc Rev. 2018 Mar 5;47(5):1874-1900
pubmed: 29376542
Nucleic Acids Res. 2005 Sep 26;33(16):5371-9
pubmed: 16186134
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Int J Nanomedicine. 2010 Nov 16;5:983-9
pubmed: 21187917
Chem Commun (Camb). 2017 Mar 30;53(27):3830-3833
pubmed: 28304043
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2576-83
pubmed: 25204262
Front Physiol. 2019 Aug 16;10:1047
pubmed: 31474879
Mol Pharm. 2017 Dec 4;14(12):4741-4750
pubmed: 29068693
Nanomedicine (Lond). 2013 Sep;8(9):1509-28
pubmed: 23914966
Nanomaterials (Basel). 2019 Oct 13;9(10):
pubmed: 31614947
Nanomedicine (Lond). 2016 Jul;11(14):1817-30
pubmed: 27388811
Nanomedicine (Lond). 2018 Apr;13(8):953-971
pubmed: 29376469
ChemMedChem. 2013 Jul;8(7):1086-92
pubmed: 23653381
Expert Rev Mol Diagn. 2013 Apr;13(3):257-69
pubmed: 23570404
Lipids. 1970 May;5(5):494-6
pubmed: 5483450
Nanomedicine. 2011 Oct;7(5):572-9
pubmed: 21704597
Bioconjug Chem. 2004 Mar-Apr;15(2):394-401
pubmed: 15025537
Anim Biotechnol. 2019 Sep 2;:1-6
pubmed: 31476967
Nat Commun. 2018 Jul 31;9(1):2997
pubmed: 30065243
Nanomedicine (Lond). 2019 Apr;14(7):835-850
pubmed: 30875274
J Control Release. 2010 Feb 25;142(1):108-21
pubmed: 19819275
Nanotechnology. 2020 Apr 3;31(14):145102
pubmed: 31810069
Tsitologiia. 2000;42(4):358-66
pubmed: 10849930
J Am Chem Soc. 2005 Aug 3;127(30):10676-85
pubmed: 16045355
Nanotechnology. 2009 Jan 28;20(4):045103
pubmed: 19417311
Inorg Chem. 2019 Feb 4;58(3):2140-2148
pubmed: 30645101
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):443-451
pubmed: 32024389
Adv Exp Med Biol. 2014;811:19-43
pubmed: 24683025
Pharmaceutics. 2019 Jan 08;11(1):
pubmed: 30625999
Nanomedicine. 2015 Oct;11(7):1851-60
pubmed: 26169150
Rep Pract Oncol Radiother. 2013 Nov 01;18(6):397-400
pubmed: 24416585
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
J Control Release. 2018 May 10;277:1-13
pubmed: 29501721
Technology (Singap World Sci). 2014 Sep;2(3):214-228
pubmed: 25379513
Nat Rev Dis Primers. 2015 Apr 23;1:15003
pubmed: 27188223
Int J Nanomedicine. 2016 Nov 01;11:5697-5708
pubmed: 27843312

Auteurs

Nuno Cruz (N)

Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

Jacinta Oliveira Pinho (JO)

Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Graça Soveral (G)

Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Lia Ascensão (L)

Centro de Estudos do Ambiente e do Mar (CESAM), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

Nuno Matela (N)

Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

Catarina Reis (C)

Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.
Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Maria Manuela Gaspar (MM)

Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Classifications MeSH